The BPAI Team
Terrence R. Cochrane, B.Sc - Director
Mr. Cochrane obtained his bachelor’s degree in Biology and Biochemistry from the University of Winnipeg in 1998. Following a brief career in environmental testing, Mr. Cochrane joined Cangene Corporation as a Quality Control Analyst where he learned the basics of GMP and biopharmaceutical development and manufacturing principals. In 2001 Mr. Cochrane was promoted to Analytical Validation Supervisor where he was responsible for forming a team and supervising validation specialists deployed for the support of analytical method and equipment validation. Mr. Cochrane was recruited to KS Avicenna, Inc. in Edmonton, Alberta in 2002 as the site Quality Assurance Manager where he was responsible for all aspects of quality and compliance for the site including operational management of the QA team and hosting corporate and regulatory inspections. In 2003 he was seconded into the Quality Control department at KS Avicenna, Inc. as Manager where he became responsible for guiding the group through an organization restructuring. Following the acquisition of the KSA site by QSV Biologics, Ltd in 2004 he was promoted to the position of Manager, Projects and Process Development, and further promoted to Director of Project Operations in 2008, where he successfully established a world-class process development team and associated project management philosophies and principals that allowed QSV to become a mid-tiered CMO over the course of five years. Following closure of QSV in 2009, Mr. Cochrane was recruited to Therapure BioPharma, Inc. in Mississauga, Ontario in the position of Director Office of Project and Process Management. With over fourteen years of life science industry experience and over ten years progressive management experience in biopharmaceutical GMP development and manufacturing, Mr. Cochrane provides a breadth of experience in the biologics industry in Quality Control, Quality Assurance, Validation, Operations, Development, Project Management and Business Development.
Arno Zeiser, MSc., Ph.D.- Associate Director, Upstream Development & Manufacturing
Dr. Zeiser obtained his Ph.D. in Biotechnology in 1996 from the Technical University of Graz, Austria following which he accepted a post-doctoral position at the Biotechnology Research Institute of Canada in Montreal Quebec where he specialized in the development and optimization of insect cell culture process. In 2001 Dr. Zeiser joined DSM Biologics in Montreal, Quebec as Senior Scientist Cell Culture where he lead upstream and midstream development of mammalian programs through the use of Hybridoma, CHO, HEK 293 and PerC6 host cell platforms. During his tenure at DSM Dr. Zeiser was responsible for technical assessments of prospective client processes, project management, scientific leadership and troubleshooting during technology transfer, scale-up and manufacturing of fed-batch and perfusion processes. In 2006 Dr. Zeiser was recruited to QSV Biologics Ltd. in Edmonton, Alberta as Senior Scientist Upstream Process Development where he was pivotal in establishing the upstream process development laboratories and associated service offerings for QSV. In this role, Dr. Zeiser expanded his expertise in mammalian to include the development and manufacturing oversight of E.coli and yeast host cell processes by managing a group of 7 scientists and associates responsible for all aspects of upstream and midstream process development. Following the closure of QSV Biologics Ltd. in 2009 Dr. Zeiser began providing expert technical consulting services for innovator companies in North America progressing novel biologics programs. With over thirteen years of life science industry experience, and over eight years of biopharmaceutical development and manufacturing experience, Dr. Zeiser brings a depth of upstream knowledge and experience to the team.
Harminder S. Mashiana, Ph.D. - Associate Director, Downstream Development & Manufacturing
Dr. Mashiana obtained his Ph.D. in Biotechnology in 1994 from the College of Basic Sciences and Humanities, Punjab Agricultural University in Ludhiana, Punjab, India. Upon immigrating to the USA he accepted a position as Biochemist with Baxter Healthcare Corp in Duarte, California in 1998 where he was responsible for planning and executing experiments aimed at supporting development of therapeutic proteins and their associated analytical procedures. Following scientific roles at BD Biosciences and Allergan between 2000 and 2001, Dr. Mashiana accepted a Staff Scientist position at Bio-Rad Laboratories, Hercules, California where he was responsible for designing, developing, optimizing and transferring purification process for the manufacturing of biologics derived from mammalian sources. Additionally, he contributed scientific expertise to the development and troubleshooting of complex immunoassays. In 2006 Dr. Mashiana was recruited to QSV Biologics, Ltd. in Edmonton Alberta as Senior Scientist Downstream Process Development where he was an initial member of the core team responsible for establishing the downstream process development laboratories and associated service offering for QSV. Throughout his tenure at QSV he was responsible for the total oversight of downstream development through to manufacturing for multiple recombinant proteins derived from a variety of different expression platform technologies while managing a world-class scientific team focused on the successful delivery of complex downstream programs. Following the closure of QSV, Dr. Mashiana joined KBI BioPharma in 2009 in the capacity of Senior Scientist Downstream Process Development and Manufacturing where he imparted his extensive knowledge of contract manufacturing. With over thirteen years of life science industry experience and more than ten years in biopharmaceutical downstream process development, Dr. Mashiana provides practical and industry based insight into challenging and complex downstream and analytical development programs.
Anke Kayser, MSc., Ph.D. - Associate Director, Upstream Development & Manufacturing
Dr. Kayser obtained her Ph.D. in Biotechnology in 1999 from the Technical University of Braunschweig, Germany. The laboratory portion of her PhD thesis about metabolic fluxes in Escherichia coli was performed at the Gesellschaft of Biotechnologische Forschung, Germany (GBF, now part of the Helmholtz Zentrum fuer Infektionsforschung (HZI)). Afterwards, Dr. Kayser accepted a post-doctoral position at the Biotechnology Research Institute of Canada in Montreal, Quebec, where she focused on the development and optimization of yeast processes. In 2001 Dr. Kayser joined DSM Biologics in Montreal, Quebec as Scientist Cell Culture where she expanded her expertise to include the development and optimization of cell culture processes by conducting upstream and midstream development of mammalian programs through the use of Hybridoma, CHO, HEK 293 and Per.C6 host cell platforms. During her tenure at DSM, Dr. Kayser was responsible for scientific leadership and troubleshooting during technology transfer, training of manufacturing staff on the process and evaluation of new platform technology. In 2006 Dr. Kayser was recruited to QSV Biologics Ltd. in Edmonton, Alberta as Senior Scientist Upstream Process Development where she was pivotal in establishing the upstream process development laboratories and associated service offerings for QSV for microbial as well as mammalian host cells. The role included management of scientists and associates, technical assessments of prospective client processes, scientific leadership and troubleshooting during technology transfer, scale-up and manufacturing of the upstream and midstream process. In 2009, Dr. Kayser accepted the role of Project Manger and Manager Upstream Development at Therapure Biopharma Inc. In this role, she established the capacity for industrial process development for mammalian cell processes at TBI, acted as project manager for the existing mammalian cell projects and initiated and oversaw the planning of a manufacturing suite for mammalian cell processes (Up-stream and downstream). With over eleven years of life science industry experience, and over nine years of biopharmaceutical development and manufacturing experience, Dr. Kayser brings a depth of upstream knowledge and experience to the team.
Frederic Morneau - Senior Consultant, GMP Manufacturing Operations
Mr. Morneau has over 15 years of professional experience in the Biotechnology and Natural Health industries. Prior to joining Bio-Processing Alliance Inc. as Senior Consultant, he served as Operations Manager with Harmonium International Inc., one of the largest manufacturers and suppliers of Probiotics in the world. In this capacity he was responsible for the management of production teams and facilities with fermentors up to 7000L with matched harvest and industrial scale product preparation equipment. At Harmonium he also contributed to general process development activities and the implementation of cGMP systems and structure. Prior to Harmonium, Mr. Morneau was the Operations Manager at QSV Biologics, an internationally recognized cGMP Biologics CMO. Mr Morneau contributed to the expansion of the Manufacturing department and led the creation and development of QSVs cGMP training program. In addition, he actively participated in the facility expansion plans for QSV in Edmonton and Brisbane, Australia. Prior to this, Mr. Morneau was the Production Supervisor for DSM Biologics, a multi-national cGMP CMO. In this role he managed and trained Upstream/Midstream personnel and was instrumental in the expansion of the department. During his work for both QSV and DSM, he was involved in the production of multiple cGMP products to support Phase I through to Phase III clinical trials, using a broad range of cell lines including microbial, mammalian and insect cells, at scales up to 3500L cultivation. With over fifteen years of life science and natural health industrial manufacturing experience, Mr. Morneau brings a depth of cGMP manufacturing operations knowledge and experience to the BPAI team.